We advised Emergent BioSolutions (NYSE:EBS) on the government contract related aspects of its acquisition of assets related to a contract with the Defense Threat Reduction Agency. Emergent BioSolutions purchased the EV-035 series of molecules, a portfolio of broad spectrum antibiotics that may fight bioterrorism agents, from Evolva Holdings SA (SIX:EVE).

Emergent BioSolutions (NYSE:EBS) is a global specialty biopharmaceutical company.